Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as a sterile solution for subcutaneous use. It is employed to prevent and treat venous thromboembolic events in patients at risk, such as those undergoing surgery or experiencing acute deep‑vein thrombosis. GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Innohep, a low molecular weight heparin, is used in several thrombo‑embolic conditions. - Deep vein thrombosis (surgical prophylaxis): prevents clot formation in postoperative patients. - Acute deep vein thrombosis (treatment): facilitates clot resolution and reduces propagation. - Pulmonary embolism (prevention and treatment): lowers the risk of embolic events in at‑risk individuals. - Medically ill patients (thrombo‑embolic prophylaxis): reduces incidence of venous thromboembolism during hospitalization.

Adverse reactions may occur with any anticoagulant therapy.

Common Side Effects: - Injection site erythema or bruising: mild local irritation after subcutaneous administration. - Minor bleeding: occasional nosebleeds or gum bleeding that resolves spontaneously. - Elevated liver enzymes: transient increase detected in routine labs.

Serious or Rare Side Effects: - Major hemorrhage: life‑threatening bleeding requiring medical intervention. - Heparin‑induced thrombocytopenia (HIT): immune‑mediated platelet decline with paradoxical clot risk. - Spontaneous spinal or epidural hematoma: rare bleeding in the spinal canal, especially after neuraxial procedures.

Careful assessment is required before initiating therapy. - Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function. - Bleeding risk: avoid in individuals with active bleeding, recent surgery, or known coagulopathy. - Pregnancy and lactation: use only if the potential benefit outweighs potential risk, as safety data are limited. - Concomitant anticoagulants: increase monitoring when combined with other blood‑thinning agents. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin may interact with several drug classes.

Major Interactions (Avoid): - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants): markedly increased bleeding risk. - Antiplatelet agents (e.g., clopidogrel, aspirin) in high‑dose regimens: synergistic hemorrhagic effect.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may prolong bleeding time. - Thrombolytic agents (e.g., alteplase): enhanced anticoagulant effect requiring close observation. - Certain antibiotics (e.g., quinolones) that affect platelet function: monitor for bleeding signs.